RT Journal Article
SR Electronic
T1 The association between immunosuppressants use and COVID-19 adverse outcome: National COVID-19 cohort in South Korea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.17.21262183
DO 10.1101/2021.08.17.21262183
A1 Shin, Hyun Joon
A1 Chow, Ronald
A1 Noh, Hyerim
A1 Lee, Jongseong
A1 Lee, Jihui
A1 Choi, Young-Geun
YR 2021
UL http://medrxiv.org/content/early/2021/08/20/2021.08.17.21262183.abstract
AB Background There is uncertainty of the effect of immunosuppression, including corticosteroids, before COVID-19 infection on COVID-19 outcomes. The aim of this study was to investigate the relationship between prehospitalization immunosuppressants use (exposure), and COVID-19 patient outcomes.Methods We conducted a population-based retrospective cohort study using a nationwide healthcare claims database of South Korea as of May 15, 2020. Confirmed COVID-19 infection in hospitalized individuals aged 40 years or older were included for analysis. We defined exposure variable by using inpatient and outpatient prescription records of immunosuppressants from the database. Our primary outcome was a composite endpoint of all-cause death, intensive care unit (ICU) admission, and mechanical ventilation use. Inverse probability of treatment weighting (IPTW)-adjusted logistic regression analyses were used, to estimate odds ratio (OR) and 95% confidence intervals, comparing immunosuppressants users and non-users.Findings We identified 4,349 patients, for which 1,356 were immunosuppressants users and 2,903 were non-users. Patients who used immunosuppressants were at increased odds of the primary outcome of all-cause death, ICU admission and mechanical ventilation use (IPTW OR 1.32; 95% CI: 1.06 – 1.63). Patients who used corticosteroids were at increased odds of the primary outcome (IPTW OR 1.33; 95% CI: 1.07 – 1.64).Interpretation We support the latest guidelines from the CDC, that people on immunosuppressants are at high risk of severe COVID-19 and immunocompromised people may need booster COVID-19 vaccinations.Funding YGC’s work was partially supported by 2020R1G1A1A01006229 awarded by the National Research Foundation of Korea.Evidence before this study It is currently unclear whether immunosuppressants use before COVID-19 is associated with adverse outcomes.Added value of this study Immunosuppressants in patients with COVID-19 were at increased odds of the primary outcome of all-cause death, ICU admission and mechanical ventilation use.Implications of all the available evidence Immunosuppressant use before COVID-19 is associated with adverse outcomes and immunocompromised people may need booster COVID-19 vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYGC's work was partially supported by 2020R1G1A1A01006229 awarded by the National Research Foundation of Korea.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Human Investigation Review Board of Public Institutional Bioethics Committee designated by the MOHW, which waived the requirement of informed consent due to retrospective study design and anonymity of the HIRA database (IRB # P01-2020-1262-001.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOn March 27, 2020, the #OpenData4COVID19 project by the Ministry of Health and Welfare (MOHW) of Korea released a patient-level, deidentified COVID-19 data based on the HIRA insurance claims database, which is the first nationwide dataset of COVID-19 patients. The HIRA COVID-19 database included data for all individuals who received a reverse transcription-polymerase chain reaction (RT-PCR) test for COVID-19 as of May 15, 2020, which was linked to their claims data for the previous three years.